Literature DB >> 12809583

[Directly observed treatment of latent tuberculosis infection: comparative study of two isoniazid regimens].

Joaquín Portilla1, Pilar Jordá, Javier Esteban, José Sánchez-Payá, Esperanza Merino, Vicente Boix.   

Abstract

INTRODUCTION: To compare compliance with two isoniazid regimens in drug users with latent tuberculosis infection. METHODS.
DESIGN: clinical trial. Group 1: isoniazid 300 mg once daily (16 patients); Group 2: isoniazid 900 mg/twice weekly (21). ENDPOINTS: compliance, toxicity and efficacy.
RESULTS: Group 1 vs. Group 2: continuation in program 81/82% (p 5 NS), compliance full doses 43.7/66.6% (p 5 0.1), median percentage of days not taking isoniazid: 1.8 (0.2-4.3) vs. 0 (0-1.7) (p 5 0.06).
CONCLUSIONS: Compliance was high in both therapeutic arms. The twice-weekly isoniazid regimen favored compliance, but differences were not significant.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12809583     DOI: 10.1016/s0213-005x(03)72943-7

Source DB:  PubMed          Journal:  Enferm Infecc Microbiol Clin        ISSN: 0213-005X            Impact factor:   1.731


  6 in total

Review 1.  Interventions for enhancing medication adherence.

Authors:  Robby Nieuwlaat; Nancy Wilczynski; Tamara Navarro; Nicholas Hobson; Rebecca Jeffery; Arun Keepanasseril; Thomas Agoritsas; Niraj Mistry; Alfonso Iorio; Susan Jack; Bhairavi Sivaramalingam; Emma Iserman; Reem A Mustafa; Dawn Jedraszewski; Chris Cotoi; R Brian Haynes
Journal:  Cochrane Database Syst Rev       Date:  2014-11-20

2.  Tuberculosis preventive therapy for people living with HIV: A systematic review and network meta-analysis.

Authors:  Mercedes Yanes-Lane; Edgar Ortiz-Brizuela; Jonathon R Campbell; Andrea Benedetti; Gavin Churchyard; Olivia Oxlade; Dick Menzies
Journal:  PLoS Med       Date:  2021-09-14       Impact factor: 11.613

3.  Eligibility for and outcome of treatment of latent tuberculosis infection in a cohort of HIV-infected people in Spain.

Authors:  Asuncion Diaz; Mercedes Diez; Maria Jose Bleda; Mikel Aldamiz; Miguel Camafort; Xabier Camino; Concepcion Cepeda; Asuncion Costa; Oscar Ferrero; Paloma Geijo; Jose Antonio Iribarren; Santiago Moreno; Maria Elena Moreno; Pablo Labarga; Javier Pinilla; Joseba Portu; Federico Pulido; Carmen Rosa; Juan Miguel Santamaría; Mauricio Telenti; Luis Trapiella; Monica Trastoy; Pompeyo Viciana
Journal:  BMC Infect Dis       Date:  2010-09-14       Impact factor: 3.090

4.  House calls by community health workers and public health nurses to improve adherence to isoniazid monotherapy for latent tuberculosis infection: a retrospective study.

Authors:  Alicia H Chang; Andrea Polesky; Gulshan Bhatia
Journal:  BMC Public Health       Date:  2013-09-28       Impact factor: 3.295

Review 5.  Efficacy and completion rates of rifapentine and isoniazid (3HP) compared to other treatment regimens for latent tuberculosis infection: a systematic review with network meta-analyses.

Authors:  Christopher Pease; Brian Hutton; Fatemeh Yazdi; Dianna Wolfe; Candyce Hamel; Pauline Quach; Becky Skidmore; David Moher; Gonzalo G Alvarez
Journal:  BMC Infect Dis       Date:  2017-04-11       Impact factor: 3.090

6.  Guidelines for the Treatment of Latent Tuberculosis Infection: Recommendations from the National Tuberculosis Controllers Association and CDC, 2020.

Authors:  Timothy R Sterling; Gibril Njie; Dominik Zenner; David L Cohn; Randall Reves; Amina Ahmed; Dick Menzies; C Robert Horsburgh; Charles M Crane; Marcos Burgos; Philip LoBue; Carla A Winston; Robert Belknap
Journal:  MMWR Recomm Rep       Date:  2020-02-14
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.